Admission C‐Reactive Protein–Albumin–Lymphocyte Index and Risk Stratification for Contrast‐Associated Acute Kidney Injury in ST‐Segment Elevation Myocardial Infarction: Comparison With the Systemic Immune‐Inflammation Index
- 19 November 2026
- journal article
- Published by Wiley in Catheterization and Cardiovascular Interventions
Abstract
Background: Many blood‐based inflammatory and nutritional indices have been linked to contrast‐associated acute kidney injury (CA‐AKI) after primary percutaneous coronary intervention (PCI) for ST‐segment elevation myocardial infarction (STEMI), but they are rarely compared with one another or tested for what they add to existing risk models. The C‐reactive protein–albumin–lymphocyte (CALLY) index and the systemic immune‐inflammation index (SII) both come from routine admission blood tests, yet no study has compared them directly for CA‐AKI or asked whether CALLY adds anything to a standard clinical model. Aims: We tested whether CALLY predicts CA‐AKI independently of SII in STEMI, and whether it improves reclassification and net benefit on top of a full clinical model. Methods: In this retrospective cohort study, we reviewed 1561 consecutive STEMI patients treated with primary PCI between 2021 and 2025. CA‐AKI was defined by the KDIGO 48‐h criterion (creatinine rise ≥ 0.3 mg/dL), with creatinine measured daily in every patient. CALLY and ln(SII) were added, alone and together, to a prespecified clinical risk model. Models were compared with the DeLong test, continuous NRI, IDI, and decision‐curve analysis. Results: CA‐AKI developed in 317 patients (20.3%). CALLY discriminated CA‐AKI better than ln(SII) (AUC 0.632 vs. 0.559; DeLong p = 0.0003). When both were entered together, CALLY stayed independent (OR 0.872, 95% CI 0.783–0.970; p = 0.012), but ln(SII) did not ( p = 0.145), even though SII was independent on its own. Adding CALLY produced only a small change in the C‐statistic (0.752–0.762; DeLong non‐significant), yet it improved reclassification (IDI 0.007, p = 0.003; NRI 0.166, p = 0.005) and net benefit, and calibration remained adequate (Hosmer–Lemeshow p ≥ 0.249). Conclusion: In STEMI patients undergoing primary PCI, a low CALLY index was independently associated with CA‐AKI and improved risk reclassification when added to a clinical model, whereas SII was not independent once CALLY was included. This is the first comparison of CALLY and SII for CA‐AKI, and the first assessment of CALLY for CA‐AKI in STEMI.This publication has 30 references indexed in Scilit:
- Inflammatory Markers and Contrast‐Induced Nephropathy Risk: A Meta‐Analysis of NLR and PLR in ACS Patients Undergoing Percutaneous Coronary InterventionCatheterization and Cardiovascular Interventions, 2025
- Risk-Stratified Prognostic Implications of Contrast-Associated Acute Kidney Injury After Percutaneous Coronary InterventionJACC: Advances, 2025
- The Prognostic Value of C‐Reactive Protein‐Albumin‐Lymphocyte (CALLY) Index in Predicting In‐Hospital Mortality After Primary Percutaneous Coronary Intervention in Patients With ST‐Elevation Myocardial Infarction (STEMI)Catheterization and Cardiovascular Interventions, 2025
- Prognostic significance of C-reactive protein-albumin-lymphocyte (CALLY) index after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarctionInternational Immunopharmacology, 2024
- Association between neutrophil percentage-to-albumin ratio and contrast-associated acute kidney injury in patients without chronic kidney disease undergoing percutaneous coronary interventionJournal of Cardiology, 2022
- Superiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinomaHPB, 2022
- Hypoalbuminemia is associated with increased risk of acute kidney injury in hospitalized patients: A meta-analysisJournal of Critical Care, 2021
- Contemporary Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary InterventionsJACC: Cardiovascular Interventions, 2014
- Renal Function-Based Contrast Dosing to Define Safe Limits of Radiographic Contrast Media in Patients Undergoing Percutaneous Coronary InterventionsJACC, 2011
- A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary interventionJACC, 2004